Literature DB >> 20350126

Advances in pharmacogenomics technologies.

C Ramana Bhasker1, Gary Hardiman.   

Abstract

The past decade has seen major advances in our understanding of genomics, with the development of newer and refined technologies. Improvements in the sensitivity and precision of DNA microarrays coupled with the emergence of massively parallel sequencing techniques have redefined how we interrogate the human genome. These tools have facilitated rapid biomarker discovery, uncovered novel targets for therapeutic intervention and enabled mechanistic studies that have helped unravel the mode of drug action. The assessment of drug toxicity based on genomic signatures associated with disease and high-throughput screening for polymorphic interindividual variability in drug responses are procedures that have greatly aided the quality of patient care. The integration of pharmacogenetic approaches for therapeutic monitoring, and health management approaches for advance clinical treatments, will be based on unique patient phenotype profiles and aimed at minimizing adverse drug reactions. In this brief commentary, the evolution and development of key genomics technologies over the past decade is reviewed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20350126     DOI: 10.2217/pgs.10.10

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  5 in total

Review 1.  Transcriptional analysis of endocrine disruption using zebrafish and massively parallel sequencing.

Authors:  Michael E Baker; Gary Hardiman
Journal:  J Mol Endocrinol       Date:  2014-06       Impact factor: 5.098

2.  Health technology assessment and private payers' coverage of personalized medicine.

Authors:  Julia R Trosman; Stephanie L Van Bebber; Kathryn A Phillips
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

Review 3.  Genomics pipelines and data integration: challenges and opportunities in the research setting.

Authors:  Jeremy Davis-Turak; Sean M Courtney; E Starr Hazard; W Bailey Glen; Willian A da Silveira; Timothy Wesselman; Larry P Harbin; Bethany J Wolf; Dongjun Chung; Gary Hardiman
Journal:  Expert Rev Mol Diagn       Date:  2017-01-25       Impact factor: 5.225

Review 4.  Integrated Genomic and Bioinformatics Approaches to Identify Molecular Links between Endocrine Disruptors and Adverse Outcomes.

Authors:  Jacopo Umberto Verga; Matthew Huff; Diarmuid Owens; Bethany J Wolf; Gary Hardiman
Journal:  Int J Environ Res Public Health       Date:  2022-01-05       Impact factor: 3.390

5.  An Introduction to Systems Analytics and Integration of Big Omics Data.

Authors:  Gary Hardiman
Journal:  Genes (Basel)       Date:  2020-02-26       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.